Cost-effectiveness of two antiviral therapies for chronic hepatitis B in Peru: Entecavir and tenofovir

Rafael Bolaños-Díaz, Romina A. Tejada, César Sanabria, Seimer Escobedo-Palza

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

1 Cita (Scopus)

Resumen

© 2017, Instituto Nacional de Salud. All rights reserved. Objetives. To compare in terms of cost-effectiveness to entecavir (ETV) and tenofovir (TDF) in the treatment of hepatitis B virus (HBV) in public hospitals in Peru. Materials and methods. We structured a Markov model. We define effectiveness adjusted life years for quality (QALY). We include the direct costs of treatment in soles from the perspective of the Ministry of Health of Peru. We estimate the relationship between cost and effectiveness ratios (ICER). We performed sensitivity analyzes considering a range of willingness to pay (WTP) from one to three times the Gross Domestic Product (GDP) per capita, and a tornado analysis regarding Monetary Net Profit (BMN) or ICER. Results. Treatment with TDF is more effective and less expensive than ETV. The ETV had a cost per QALY of PEN 4482, and PEN 1526 TDF. The PTO maintains a progressively larger with increasing WTP BMN. The discount rate was the only variable with a significant effect on model uncertainty. Conclusion: Treatment with TDF is more cost-effective than ETV in public hospitals in Peru.
Idioma originalInglés estadounidense
Páginas (desde-hasta)377-385
Número de páginas9
PublicaciónRevista Peruana de Medicina Experimental y Salud Publica
DOI
EstadoPublicada - 1 jul. 2017

Huella

Profundice en los temas de investigación de 'Cost-effectiveness of two antiviral therapies for chronic hepatitis B in Peru: Entecavir and tenofovir'. En conjunto forman una huella única.

Citar esto